phase

Hyatt Advances Next Phase of Growth in India and Southwest Asia with New Senior Leadership Appointment

Appointment of Vikas Chawla builds on significant growth with nearly 5,000 rooms added in 2025 to Hyatt's India and Southwest…

1 month ago

Tejas Networks completes delivery of 17,000 IP/MPLS routers for BharatNet Phase III

BENGALURU, India, March 30, 2026 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that the company has reached a…

1 month ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…

1 month ago

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

March 28, 2026 15:00 ET  | Source: Roivant Sciences The results of the Phase 3 VALOR trial were published in…

1 month ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 18, 2026 19:34 ET  | Source: Vaxcyte, Inc. Based on the Strength of Unprecedented Results from the Positive Phase…

2 months ago

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA),…

2 months ago

Otelier Adds Ani Gujrathi as Chief Technology & Product Officer to Drive Next Phase of Innovation

With more than 20 years of experience scaling B2B SaaS, modernizing platforms, and driving AI-first transformation, Gujrathi will lead Otelier's…

2 months ago

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimers Disease at AD/PD 2026

March 10, 2026 08:05 ET  | Source: NKGen Biotech, Inc. SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen…

2 months ago

CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 March 09, 2026 10:21 ET…

2 months ago